Does Coverage Of Renal Intervention Hinder Trials? Stakeholders Disagree
This article was originally published in The Gray Sheet
Executive Summary
Stakeholders are split on whether Medicare should continue covering percutaneous renal artery intervention or limit it in order to encourage enrollment in randomized trials